OVERVIEW
Percutaneous electrical nerve stimulation (PENS) and percutaneous neuromodulation therapy (PNT) combine the features of electroacupuncture and transcutaneous electrical nerve stimulation. PENS is performed with needle electrodes while PNT uses very fine needle-like electrode arrays placed in close proximity to the painful area to stimulate peripheral sensory nerves in the soft tissue for the treatment of chronic pain conditions.

PRIOR AUTHORIZATION
Not applicable

POLICY STATEMENT
BlueCHiP for Medicare and Commercial Product
Percutaneous electrical neurostimulation (PEN) or percutaneous neuromodulation therapy (PNT) for the treatment of chronic pain conditions is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

MEDICAL CRITERIA
Not applicable

COVERAGE
BlueCHiP for Medicare and Commercial Products
Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement, or Benefit Booklet for limitations of benefits/coverage when services are not medically necessary.

BACKGROUND
Percutaneous electrical nerve stimulation (PENS) and percutaneous neuromodulation therapy (PNT) have been evaluated for the treatment of a variety of chronic musculoskeletal or neuropathic pain conditions including low back pain, neck pain, diabetic neuropathy, chronic headache, and surface hyperalgesia. Chronic pain presents a substantial burden to patients, adversely affecting function and quality of life. These chronic pain conditions have typically failed other treatments, and the goal of treatment with PENS and PNT is to relieve unremitting pain.

PENS is similar in concept to transcutaneous electrical nerve stimulation but differs in that needles are inserted either around or immediately adjacent to the nerves serving the painful area and are then stimulated. PENS is generally reserved for patients who fail to get pain relief from TENS. PENS is also distinguished from acupuncture with electrical stimulation. In electrical acupuncture, needles are also inserted just below the skin, but the placement of needles is based on specific theories regarding energy flow throughout the human body. In PENS, the location of stimulation is determined by proximity to the pain.

PNT is a variant of PENS in which fine filament electrode arrays are placed near the area causing pain. Some use the terms PENS and PNT interchangeably. It is proposed that PNT inhibits pain transmission by
creating an electrical field that hyperpolarizes C fibers, thus preventing action potential propagation along the pain pathway.

For individuals who have chronic pain conditions (eg, back, neck, neuropathy, headache, hyperalgesia, knee osteoarthritis) who receive PENS, the evidence includes primarily small controlled trials. Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. In the highest quality trial of PENS conducted to date, no difference in outcomes was found between the active (30 minutes of stimulation with 10 needles) and the sham (5 minutes of stimulation with 2 needles) treatments. Smaller trials, which have reported positive results, are limited by unclear blinding and short-term follow-up. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have chronic pain conditions (eg, back, neck, neuropathy, headache, hyperalgesia, knee osteoarthritis) who receive PNT, the evidence consists of 1 randomized controlled trial. Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. The single trial is limited by lack of investigator blinding, unclear participant blinding, and short-term follow-up. The evidence is insufficient to determine the effects of the technology on health outcomes.

**REGULATORY STATUS**

In 2002, the Percutaneous Neuromodulation Therapy™ (Vertis Neuroscience) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. The labeled indication is: “Percutaneous neuromodulation therapy (PNT) is indicated for the symptomatic relief and management of chronic or intractable pain and/or as an adjunctive treatment in the management of post-surgical pain and post-trauma pain.” In 2006, the Deepwave® Percutaneous Neuromodulation Pain Therapy System (Biowave) was cleared for marketing by FDA through the 510(k) process. FDA determined that this device was substantially equivalent to the Vertis neuromodulation system and a Biowave neuromodulation therapy unit. The Deepwave® system includes a sterile single-use percutaneous electrode array that contains 1014 microneedles in a 1.5-inch diameter area. The needles are 736 μm (0.736 mm) in length; the patch is reported to feel like sandpaper or Velcro. FDA product code: NHI.

**CODING**

BlueCHiP for Medicare and Commercial Products

There is not a specific code for PENS or PNT, use the unlisted code below following the unlisted process 64999: Unlisted procedure, nervous system

**RELATED POLICIES**
Transcutaneous Electrical Nerve Stimulation
Interferential Current Stimulation
Peripheral Subcutaneous Field Stimulation
Cranial Electrotherapy Stimulation and Auricular Electrostimulation

**PUBLISHED**

Provider Update, June 2017

**REFERENCES**

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Transcutaneous electric nerve stimulation (TENS) or percutaneous electric nerve stimulation (PENS) in the treatment of chronic and postoperative pain TEC Assessments. 1996;Volume 11:Tab 21.

3. Weiner DK, Rudy TE, Glick RM, et al. Efficacy of percutaneous electrical nerve stimulation for the
12752833

transcutaneous electrical nerve stimulation for long-term pain relief in patients with chronic low back pain.


randomized crossover study. JAMA. Mar 3 1999;281(9):818-823. PMID 10071003


percutaneous electrical nerve stimulation in patients with chronic low back pain. Anesth Analg. Apr
1999;88(4):841-846. PMID 10195535

9. White PF, Craig WF, Vakharia AS, et al. Percutaneous neuromodulation therapy: does the location of
11004055


11. Ahmed HE, White PF, Craig WF, et al. Use of percutaneous electrical nerve stimulation (PENS) in the

2011;12(10):1515-1522. PMID 21883874

low back pain patients with a subacute duration of lower extremity pain. Paper presented at: American
Academy of Pain Medicine Annual Meeting; 2002; San Francisco, CA.

percutaneous neuromodulation pain therapy device versus sham for the osteoarthritic knee: a pilot study.

15. National Institute for Health and Care Excellence (NICE). Percutaneous electrical nerve stimulation for
17, 2017.

neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular
and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.
Neurology. May 17 2011;76(20):1758-1765. PMID 21482920
